2011
DOI: 10.1016/j.jchromb.2010.11.011
|View full text |Cite
|
Sign up to set email alerts
|

Development and validation of a HPLC method for the quantification of baculovirus particles

Abstract: A HPLC method using an anion exchange column was developed for the quantification of baculovirus particles. To properly detect the virus eluting from the column, a nucleic acid dye was used to amplify the signal projected by the virus. The viral genome was labeled by incubating the virus with SYBR Green I at 37 • C for a minimum of 1 h. The virus was specifically eluted from the contaminants in 8.9 min at a NaCl concentration of 480 mM NaCl (in 20 mM Tris-HCl, pH 7.5). The total run time of the method was 25 m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
6
2

Relationship

2
6

Authors

Journals

citations
Cited by 17 publications
(13 citation statements)
references
References 31 publications
(39 reference statements)
0
13
0
Order By: Relevance
“…Ion exchange (IEX)-HPLC has been developed for the particle quantification of viral vectors for gene therapy and cancer therapy treatments produced in mammalian cell culture [17][18][19][20][21][22]. The use of this method in our group as an in-process monitoring tool was proven to be invaluable in the successful scale up of viral products that reached commercialization (ONRAB by Artemis Technologies, Canada) or are currently in late stage of clinical evaluation (Reolysin by Oncolytic Biotech., Canada).…”
Section: Introductionmentioning
confidence: 99%
“…Ion exchange (IEX)-HPLC has been developed for the particle quantification of viral vectors for gene therapy and cancer therapy treatments produced in mammalian cell culture [17][18][19][20][21][22]. The use of this method in our group as an in-process monitoring tool was proven to be invaluable in the successful scale up of viral products that reached commercialization (ONRAB by Artemis Technologies, Canada) or are currently in late stage of clinical evaluation (Reolysin by Oncolytic Biotech., Canada).…”
Section: Introductionmentioning
confidence: 99%
“…This includes the use of ultrafiltration membranes, ion exchange membranes and resin-based chromatography (Barsoum, 1999;Michalsky et al, 2009;Transfiguracion et al, 2011;Wu et al, 2007). However, the purification of AcMPNV is developed poorly (Vicente et al, 2010;Vicente et al, 2009) and materials and processes for the efficient downstream processing of baculoviruses for clinical applications is sought (Vicente et al, 2010;Vicente et al, 2009).…”
Section: Introductionmentioning
confidence: 99%
“…In one case, a bioreactor is a vessel in which a chemical process is carried out which involves organisms or biochemically active substances derived from such organisms. This process can either be aerobic or anaerobic [12]. These bioreactors are commonly cylindrical, ranging in size from liters to cubic meters, and are often made of stainless steel.…”
Section: Bioreactormentioning
confidence: 99%
“…The aspect ratio (H/D) of stirred vessels varies over a wide range. When aeration is required, the aspect ratio is usually increased [11,12,14]. This provides for longer contact times between the rising bubbles and liquid and produces a greater hydrostatic pressure at the bottom of the vessel.…”
Section: Continuous Stirred Tank Bioreactormentioning
confidence: 99%